These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 25280564)

  • 21. Evolution of neoplastic cell lineages in Barrett oesophagus.
    Barrett MT; Sanchez CA; Prevo LJ; Wong DJ; Galipeau PC; Paulson TG; Rabinovitch PS; Reid BJ
    Nat Genet; 1999 May; 22(1):106-9. PubMed ID: 10319873
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.
    Akagi T; Ito T; Kato M; Jin Z; Cheng Y; Kan T; Yamamoto G; Olaru A; Kawamata N; Boult J; Soukiasian HJ; Miller CW; Ogawa S; Meltzer SJ; Koeffler HP
    Int J Cancer; 2009 Nov; 125(10):2349-59. PubMed ID: 19670330
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma.
    Stachler MD; Camarda ND; Deitrick C; Kim A; Agoston AT; Odze RD; Hornick JL; Nag A; Thorner AR; Ducar M; Noffsinger A; Lash RH; Redston M; Carter SL; Davison JM; Bass AJ
    Gastroenterology; 2018 Jul; 155(1):156-167. PubMed ID: 29608884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma.
    Bani-Hani K; Martin IG; Hardie LJ; Mapstone N; Briggs JA; Forman D; Wild CP
    J Natl Cancer Inst; 2000 Aug; 92(16):1316-21. PubMed ID: 10944553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue.
    Galipeau PC; Prevo LJ; Sanchez CA; Longton GM; Reid BJ
    J Natl Cancer Inst; 1999 Dec; 91(24):2087-95. PubMed ID: 10601379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Fontolliet C; Bosman FT; Benhattar J
    Gastroenterology; 2002 Apr; 122(4):1113-21. PubMed ID: 11910361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
    Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
    Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical significance of p53 tumor suppressor gene mutations in adenocarcinoma in Barrett esophagus].
    Schneider PM; Hölscher AH; Wegerer S; König U; Becker K; Siewert JR
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):495-9. PubMed ID: 14518305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.
    Maley CC; Galipeau PC; Li X; Sanchez CA; Paulson TG; Blount PL; Reid BJ
    Cancer Res; 2004 Oct; 64(20):7629-33. PubMed ID: 15492292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.
    Brankley SM; Halling KC; Jenkins SM; Timmer MR; Iyer PG; Smyrk TC; Barr Fritcher EG; Voss JS; Kipp BR; Campion MB; Lutzke LS; Minot DM; Wang KK
    Dis Esophagus; 2016 Aug; 29(6):513-9. PubMed ID: 26043762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus.
    Levine DM; Ek WE; Zhang R; Liu X; Onstad L; Sather C; Lao-Sirieix P; Gammon MD; Corley DA; Shaheen NJ; Bird NC; Hardie LJ; Murray LJ; Reid BJ; Chow WH; Risch HA; Nyrén O; Ye W; Liu G; Romero Y; Bernstein L; Wu AH; Casson AG; Chanock SJ; Harrington P; Caldas I; Debiram-Beecham I; Caldas C; Hayward NK; Pharoah PD; Fitzgerald RC; Macgregor S; Whiteman DC; Vaughan TL
    Nat Genet; 2013 Dec; 45(12):1487-93. PubMed ID: 24121790
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
    Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
    Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
    Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
    Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
    Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus.
    Li X; Paulson TG; Galipeau PC; Sanchez CA; Liu K; Kuhner MK; Maley CC; Self SG; Vaughan TL; Reid BJ; Blount PL
    Cancer Prev Res (Phila); 2015 Sep; 8(9):845-56. PubMed ID: 26130253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active human papillomavirus involvement in Barrett's dysplasia and oesophageal adenocarcinoma is characterized by wild-type p53 and aberrations of the retinoblastoma protein pathway.
    Rajendra S; Yang T; Xuan W; Sharma P; Pavey D; Lee CS; Le S; Collins J; Wang B
    Int J Cancer; 2017 Nov; 141(10):2037-2049. PubMed ID: 28722212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett's esophagus cohort.
    Lomo LC; Blount PL; Sanchez CA; Li X; Galipeau PC; Cowan DS; Ayub K; Rabinovitch PS; Reid BJ; Odze RD
    Am J Surg Pathol; 2006 Apr; 30(4):423-35. PubMed ID: 16625087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis.
    Gu J; Ajani JA; Hawk ET; Ye Y; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Wang KK; Wu X
    Cancer Prev Res (Phila); 2010 Sep; 3(9):1176-86. PubMed ID: 20651033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.